JP2020521452A - 標的化免疫寛容 - Google Patents

標的化免疫寛容 Download PDF

Info

Publication number
JP2020521452A
JP2020521452A JP2019564880A JP2019564880A JP2020521452A JP 2020521452 A JP2020521452 A JP 2020521452A JP 2019564880 A JP2019564880 A JP 2019564880A JP 2019564880 A JP2019564880 A JP 2019564880A JP 2020521452 A JP2020521452 A JP 2020521452A
Authority
JP
Japan
Prior art keywords
polypeptide
molecule
binding
mutation
mutein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019564880A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020521452A5 (enExample
Inventor
ジョアン・エル・ヴィニー
ネイサン・ヒギンソン−スコット
Original Assignee
パンディオン・セラピューティクス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パンディオン・セラピューティクス・インコーポレイテッド filed Critical パンディオン・セラピューティクス・インコーポレイテッド
Publication of JP2020521452A publication Critical patent/JP2020521452A/ja
Publication of JP2020521452A5 publication Critical patent/JP2020521452A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019564880A 2017-05-24 2018-05-24 標的化免疫寛容 Pending JP2020521452A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762510586P 2017-05-24 2017-05-24
US62/510,586 2017-05-24
US201762510816P 2017-05-25 2017-05-25
US62/510,816 2017-05-25
US201762558175P 2017-09-13 2017-09-13
US62/558,175 2017-09-13
US201762595352P 2017-12-06 2017-12-06
US62/595,352 2017-12-06
PCT/US2018/034334 WO2018217989A1 (en) 2017-05-24 2018-05-24 Targeted immunotolerance

Publications (2)

Publication Number Publication Date
JP2020521452A true JP2020521452A (ja) 2020-07-27
JP2020521452A5 JP2020521452A5 (enExample) 2021-07-26

Family

ID=64395920

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019564880A Pending JP2020521452A (ja) 2017-05-24 2018-05-24 標的化免疫寛容

Country Status (12)

Country Link
US (2) US10676516B2 (enExample)
EP (1) EP3630163A4 (enExample)
JP (1) JP2020521452A (enExample)
KR (1) KR20200010354A (enExample)
CN (1) CN111010866A (enExample)
AU (1) AU2018273914A1 (enExample)
BR (1) BR112019024127A2 (enExample)
CA (1) CA3064435A1 (enExample)
IL (1) IL270741A (enExample)
MX (1) MX2019013517A (enExample)
SG (1) SG11201909949XA (enExample)
WO (1) WO2018217989A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021507690A (ja) * 2017-12-06 2021-02-25 パンディオン・オペレーションズ・インコーポレイテッド Ｉｌ−２ムテインおよびその使用
JP2024524534A (ja) * 2021-07-09 2024-07-05 ブライト ピーク セラピューティクス エージー 炎症性疾患及び自己免疫疾患の治療のための修飾ｉｌ－２ポリペプチド

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180185444A1 (en) * 2014-09-05 2018-07-05 Gemma Alexandra Figtree Methods for treatment and prevention of vascular disease
EP3511340B1 (en) 2016-08-10 2024-10-02 Ajou University Industry-Academic Cooperation Foundation Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
US20210277085A1 (en) * 2017-05-24 2021-09-09 Pandion Therapeutics, Inc. Targeted immunotolerance
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
KR102777151B1 (ko) 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3720871A4 (en) * 2017-12-06 2021-09-15 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2020061142A1 (en) * 2018-09-18 2020-03-26 Pandion Therapeutics, Inc. Targeted immunotolerance
KR20210080460A (ko) * 2018-10-23 2021-06-30 드래곤플라이 쎄라퓨틱스, 인크. 이종이량체성 Fc-융합된 단백질
TW202034945A (zh) * 2018-12-21 2020-10-01 大陸商江蘇恆瑞醫藥股份有限公司 一種人白細胞介素２變體或其衍生物
CN113924311A (zh) * 2019-01-07 2022-01-11 印希比股份有限公司 包含修饰的il-2多肽的多肽及其用途
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス，インコーポレーテッド ＮＫｐ３０に結合する抗体分子およびその使用
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
WO2020256868A1 (en) * 2019-05-16 2020-12-24 Trustees Of Boston University Immune system modulators for the treatment of squamous lung premalignancy
AU2020279240A1 (en) * 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
JP7778571B2 (ja) * 2019-06-05 2025-12-02 アッシャー バイオセラピューティクス， インコーポレイテッド 免疫細胞機能をモジュレートするための変異体インターロイキン－２ポリペプチドと抗原結合分子の融合体
WO2020252421A2 (en) * 2019-06-14 2020-12-17 Cugene, Inc. Novel interleukin-2 variants and bifunctional fusion molecules thereof
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
CN114555634B (zh) 2019-08-13 2025-01-10 美国安进公司 用于扩增调节性t细胞的白介素-2突变蛋白
AU2020329933A1 (en) * 2019-08-15 2022-03-24 Cytimm Therapeutics, Inc. Modified interleukin 2 (IL-2) polypeptides, conjugates and uses thereof
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
WO2021133036A1 (ko) 2019-12-23 2021-07-01 주식회사 엘지화학 항-lilrb1 항체 및 그의 용도
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
KR20220140514A (ko) 2020-01-10 2022-10-18 브라이트 피크 테라퓨틱스 아게 변형된 il-2 폴리펩타이드 및 그의 용도
CN115362168A (zh) 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物
WO2021168192A2 (en) * 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with pd-1 agonists or il-2 muteins
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
EP4229078A4 (en) * 2020-10-16 2025-03-19 Pandion Operations, Inc. Skin targeted immunotolerance
EP4229097A4 (en) * 2020-10-16 2025-04-23 Pandion Operations, Inc. IMMUNOTOLERANCY TARGETING THE KIDNEY
KR20230112632A (ko) 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
CA3203977A1 (en) 2020-12-04 2022-06-09 Visterra, Inc. Methods of using interleukin-2 agents
TW202241932A (zh) * 2020-12-23 2022-11-01 美商默沙東藥廠 用於治療自體免疫及發炎性疾病之il-2突變蛋白
WO2022221746A1 (en) * 2021-04-16 2022-10-20 Orionis Biosciences, Inc. Il-2 based constructs
WO2022235622A2 (en) * 2021-05-04 2022-11-10 Biocove Llc Cd20 targeting fusion proteins and methods of use thereof
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
TW202333772A (zh) 2021-12-01 2023-09-01 美商威特拉公司 使用介白素-2藥劑之方法
AU2023226512A1 (en) 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Immune antigen specific il-18 immunocytokines and uses thereof
IL317511A (en) 2022-06-16 2025-02-01 Cephalon Llc IL-2 immunoconjugates attenuated by anti-PD-1 antibody and their uses
WO2025222144A1 (en) * 2024-04-18 2025-10-23 Fred Hutchinson Cancer Center Antibodies and vaccines having vh3-21 and vl1-40 binding domains and uses thereof
WO2025254932A1 (en) * 2024-06-03 2025-12-11 Pharmaessentia Corporation Selective treg stimulator and methods of uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008505606A (ja) * 2004-01-09 2008-02-28 ファイザー インコーポレイティッド ＭＡｄＣＡＭに対する抗体
JP2012515778A (ja) * 2009-01-21 2012-07-12 アムジェン インコーポレイテッド 炎症性疾患および自己免疫疾患の処置の組成物および方法
JP2016514161A (ja) * 2013-03-14 2016-05-19 アムジエン・インコーポレーテツド アグリコシル化Ｆｃ含有ポリペプチド

Family Cites Families (309)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853332A (en) 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
FI82266C (fi) 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4572798A (en) 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
CA1340265C (en) 1985-01-18 1998-12-15 Kirston E. Koths Oxidation resistant muteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4816440A (en) 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
US4863727A (en) 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US5098702A (en) 1986-04-09 1992-03-24 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US5425940A (en) 1986-04-09 1995-06-20 Cetus Oncology Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US4894226A (en) 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
AU3285989A (en) 1987-11-25 1989-06-14 Cetus Corporation Treatment of infections caused by a primary immunodeficiency with interleukin-2
US5066489A (en) 1988-03-28 1991-11-19 Cetus Corporation Combination therapy of IL-2 and DTIC for the treatment of melanoma
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5153310A (en) 1989-02-28 1992-10-06 Du Pont Merck Pharmaceutical Company Il-2 analogs containing n-linked glycosylation sites
NZ234674A (en) 1989-08-02 1992-02-25 Seragen Inc Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
JPH11510046A (ja) 1995-07-21 1999-09-07 ローヌ−プーラン ローラー ファーマシューティカルズ インコーポレイテッド アデノ関連ウイルスリポソーム及び樹状細胞をトランスフェクトして特異性免疫を刺激することにおけるそれらの使用
US20040115128A1 (en) 1995-09-08 2004-06-17 Schnitzer Jan E. Targeting endothelium for tissue-specific delivery of agents
EP1442750B1 (en) 1997-11-20 2012-08-01 Vical Incorporated Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
JP2001523480A (ja) 1997-11-20 2001-11-27 バイカル インコーポレイテッド サイトカイン発現ポリヌクレオチドおよびそれらの組成物を用いた癌の処置
US6232287B1 (en) 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
US6455677B1 (en) 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US7138103B2 (en) 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
ES2207278T3 (es) 1998-07-28 2004-05-16 Micromet Ag Heterominicuerpos.
US6294349B1 (en) 1999-03-01 2001-09-25 University Of Mississippi Medical Ctr. Method of diagnosing and monitoring malignant breast carcinomas
US6348192B1 (en) 1999-05-11 2002-02-19 Bayer Corporation Interleukin-2 mutein expressed from mammalian cells
CZ305123B6 (cs) 1999-10-04 2015-05-13 Novartis Vaccines And Diagnostics, Inc. Způsob výroby kapalného farmaceutického prostředku
WO2001053354A2 (en) * 2000-01-20 2001-07-26 Chiron Corporation Methods for treating tumors using a fusion protein comprising il-2- polypeptides and p185-specific binding molecules
US7306801B2 (en) 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
US6579521B2 (en) 2000-10-20 2003-06-17 Chiron Corporation Methods of therapy for HIV infection
BR0209177A (pt) * 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
AU2002312410A1 (en) 2001-06-08 2002-12-23 Target Protein Technologies, Inc. Tissue-specific endothelial membrane proteins
CA2456470A1 (en) 2001-08-13 2003-02-27 University Of Southern California Interleukin-2 mutants with reduced toxicity
US20020187512A1 (en) 2001-09-10 2002-12-12 Nagem Ronaldo Alves Pinto Crystal structure of human interleukin-22
EP1454138B1 (en) 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
WO2004003140A2 (en) 2002-01-18 2004-01-08 Zymogenetics, Inc. Cytokine receptor zcytor17 multimers
WO2004022593A2 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US20070202097A1 (en) 2003-03-10 2007-08-30 Krissansen Geoffrey W Monoclonal Antibodies That Recognise Mucosal Addressin Cell Adhesion Molecule-1 (Madcam-1), Soluble Madcam-1 And Uses Thereof
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
DE602004031341D1 (de) 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
ES2356154T3 (es) 2003-07-21 2011-04-05 Transgene S.A. Citoquinas multifuncionales.
KR100632985B1 (ko) 2003-07-26 2006-10-11 메덱스젠 주식회사 생리활성 조절 단백질의 효능 향상 방법 및 그 예시변이체들
US20050069521A1 (en) 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
US8454963B2 (en) 2003-11-13 2013-06-04 Musc Foundation For Research Development Tissue targeted complement modulators
JP2007515185A (ja) 2003-12-22 2007-06-14 カイロン コーポレイション 免疫応答障害に対する処置ストラテジーのための診断法としてのＦｃレセプター多型の使用
KR20070003934A (ko) 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
WO2005113595A2 (en) 2004-05-19 2005-12-01 Avidex Ltd High affinity ny-eso t cell receptor
WO2005117977A2 (en) 2004-06-02 2005-12-15 Sidney Kimmel Cancer Center Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface
ES2432141T3 (es) 2005-01-27 2013-11-29 Novartis Vaccines And Diagnostics, Inc. Procedimientos para tratar carcinoma de células renales
BRPI0607351A2 (pt) 2005-02-15 2009-09-01 Novartis Vaccines & Diagnostic métodos para tratamento de linfomas empregando uma combinação de agente quimioterapêutico e il-2 e opcionalmente um anticorpo anti-cd20
EP1865986B1 (en) 2005-03-08 2016-02-17 Pfizer Products Inc. Anti-ctla-4 antibody compositions
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2007001677A2 (en) * 2005-05-17 2007-01-04 University Of Connecticut Compositions and methods for immunomodulation in an organism
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
DK2027155T3 (en) 2006-06-06 2016-05-09 Crucell Holland Bv HUMAN BINDING MOLECULES with killer activity against staphylococci and uses thereof
JP2009542592A (ja) 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法
WO2008085987A2 (en) 2007-01-09 2008-07-17 The Trustees Of The University Of Pennsylvania Drug delivery to human tissues by single chain variable region antibody fragments cloned by phage display
WO2008097439A2 (en) 2007-02-07 2008-08-14 The Trustees Of The University Of Pennsylvania Anti-autoimmune antibodies for treatment of pemphigus
JP5650406B2 (ja) 2007-03-07 2015-01-07 ユーティーアイ リミテッド パートナーシップ 自己免疫状態の予防および治療のための組成物および方法
WO2008124858A2 (en) 2007-04-11 2008-10-23 F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. Targeted receptor
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
US8846867B2 (en) 2007-06-26 2014-09-30 The Trustees Of The University Of Pennsylvania Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies
WO2009061853A2 (en) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
EP2225397A4 (en) 2007-11-28 2011-08-17 Univ Montreal PD-1 MODULATION AND USES THEREOF
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
AU2009290543B2 (en) 2008-09-12 2015-09-03 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
AU2009298131B2 (en) 2008-10-02 2016-07-14 Aptevo Research And Development Llc CD86 antagonist multi-target binding proteins
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
JP2012506394A (ja) 2008-10-21 2012-03-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 放射線および免疫サイトカインによる癌治療
WO2010117423A2 (en) 2009-03-31 2010-10-14 Duke University A METHOD FOR TREATING A PATIENT HAVING OR AT RISK FOR DEVELOPING A DISORDER ASSOCIATED WITH DECREASED EXPRESSION OF ß2 ADRENERGIC RECEPTORS OR NEED FOR INCREASED ß2 ADRENERGIC RECEPTOR ACTIVITY
WO2011020047A1 (en) 2009-08-14 2011-02-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of il-15 to increase thymic output and to treat lymphopenia
CU23734A1 (es) 2009-11-27 2011-11-15 Centro Inmunologia Molecular Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
EP3904391B1 (en) 2010-03-10 2024-07-10 Genmab A/S Monoclonal antibodies against c-met
CN102892786B (zh) 2010-03-11 2016-03-16 Ucb医药有限公司 Pd-1抗体
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
CU23923B1 (es) 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
ES2866674T3 (es) 2010-11-12 2021-10-19 Nektar Therapeutics Conjugados de una fracción de IL-2 y un polímero
WO2012088446A1 (en) 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
US20120207733A1 (en) 2011-02-14 2012-08-16 Allergan, Inc. Treating a Disease of Hyperproliferation Using Retargeted Endopeptidases
WO2012119093A1 (en) 2011-03-03 2012-09-07 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
AU2012222833B2 (en) 2011-03-03 2017-03-16 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
US9669071B2 (en) 2011-03-11 2017-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for stimulating T lymphocytes with IL-2
EP3443979B2 (en) 2011-03-11 2026-05-20 Assistance Publique - Hôpitaux De Paris IL-2 DOSAGE REGIMEN FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
WO2012163519A1 (en) 2011-05-27 2012-12-06 Dutalys Antibodies with improved folding stability
EP2726494B1 (en) 2011-06-28 2017-01-04 Whitehead Institute For Biomedical Research Using sortases to install click chemistry handles for protein ligation
WO2013022091A1 (ja) 2011-08-11 2013-02-14 小野薬品工業株式会社 Ｐｄ－１アゴニストからなる自己免疫疾患治療剤
US20140248372A1 (en) 2011-09-19 2014-09-04 Emory University Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
CN104507968B (zh) 2012-04-27 2019-02-05 诺和诺德股份有限公司 人cd30配体抗原结合蛋白
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
WO2013189516A1 (en) 2012-06-18 2013-12-27 Apeiron Biologics Ag Method for treating a gd2 positive cancer
WO2014004586A1 (en) 2012-06-25 2014-01-03 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
EP2866826B1 (en) 2012-06-27 2025-08-06 Meiragtx UK II Limited Combination for treating an inflammatory disorder
IN2015DN01115A (enExample) 2012-07-13 2015-06-26 Zymeworks Inc
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
PL3434695T3 (pl) 2012-08-07 2021-05-17 Roche Glycart Ag Ulepszona immunoterapia
WO2014085947A1 (zh) 2012-12-05 2014-06-12 Chiou Shiow-Her 趋化素-细胞素融合蛋白和其应用
WO2014100014A1 (en) 2012-12-17 2014-06-26 The Board Of Trustees Of The Leland Stanford Junior University Super-2 complexes with antibody to augment il-2 therapy
EP2950814A4 (en) 2013-01-31 2016-06-08 Univ Jefferson FUSION PROTEINS BASED ON PD-L1 AND PD-L2 AND USES THEREOF
US20150259416A1 (en) 2014-03-12 2015-09-17 Biocrine Ab Methods for treating and/or limiting development of diabetes
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
EP2968450A4 (en) 2013-03-15 2016-10-26 Angelica Therapeutics Inc MODIFIED TOXINS
EP3421495A3 (en) 2013-03-15 2019-05-15 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US10260038B2 (en) 2013-05-10 2019-04-16 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
EP3029065B1 (en) 2013-06-06 2020-05-27 Hefei Lifeon Pharmaceutical Co. Ltd. Human antibody against ed-b domain of fibronectin and uses thereof
WO2015066543A1 (en) 2013-11-01 2015-05-07 Board Of Regents, The University Of Texas System Targeting her2 and her3 with bispecific antibodies in cancerous cells
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
PT3102595T (pt) 2014-02-06 2019-01-11 Hoffmann La Roche Proteínas de fusão de interleucina-2 e suas utilizações
EP3105333B1 (en) 2014-02-10 2020-04-08 Emory University Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
ES2864124T3 (es) 2014-03-11 2021-10-13 Molecular Templates Inc Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
EP2918285A1 (en) 2014-03-11 2015-09-16 Université Pierre et Marie Curie (Paris 6) Interleukin-2 for treating food allergy
JP6592505B2 (ja) 2014-04-24 2019-10-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
KR102496206B1 (ko) 2014-06-11 2023-02-06 몰레큘러 템플레이츠, 인코퍼레이션. 프로테아제-절단 저항성의 시가 독소 a 서브유닛 작동체 폴리펩티드 및 이를 포함하는 세포-표적화 분자
EP2963057A1 (en) 2014-07-02 2016-01-06 Calypso Biotech SA Antibodies to IL-15
KR102493543B1 (ko) 2014-07-21 2023-01-30 데리니아, 인크. 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자
ES2743809T3 (es) 2014-07-31 2020-02-20 Amgen Res Munich Gmbh Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados
PT3177644T (pt) 2014-08-05 2021-01-13 MabQuest SA Reagentes imunológicos que se ligam a pd-1
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
JP6640834B2 (ja) 2014-08-11 2020-02-05 デリニア， インコーポレイテッド 自己免疫疾患の処置のために調節性ｔ細胞を選択的に活性化させる改変ｉｌ−２変異体
EP3180018B1 (en) 2014-08-12 2019-07-24 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
ES2774380T3 (es) * 2014-08-29 2020-07-20 Hoffmann La Roche Politerapia de inmunocitocinas de variante de IL-2 dirigida a tumor y anticuerpos frente a PD-L1 humano
PL3590962T3 (pl) 2014-10-23 2022-01-31 Singh Molecular Medicine, Llc Przeciwciała jednodomenowe przeciwko antygenom wewnątrzkomórkowym
WO2016100375A2 (en) 2014-12-15 2016-06-23 Washington University Compositions and methods for targeted cytokine delivery
CA2971734C (en) 2014-12-22 2025-11-18 Pd-1 Acquisition Group, Llc Anti-pd-1 antibodies
US20160206666A1 (en) 2014-12-22 2016-07-21 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
CA2916283C (en) * 2015-01-09 2024-07-02 Pfizer Inc. MADCAM ANTAGONIST DOSING REGIMEN
WO2016115168A1 (en) 2015-01-12 2016-07-21 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
CN113527495A (zh) 2015-04-08 2021-10-22 索伦托药业有限公司 与cd38结合的抗体治疗剂
IL304950A (en) 2015-04-10 2023-10-01 Amgen Inc Interleukin for the expansion of myotonic control T-2 cells
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
WO2016179430A1 (en) 2015-05-05 2016-11-10 Rubicon Biotechnology Llc Cancer immunotherapeutic
GB201507908D0 (en) 2015-05-08 2015-06-24 Philogen Spa IL2 and TNF immunoconjugates
DK3298043T3 (da) 2015-05-18 2021-02-15 Ab Initio Biotherapeutics Inc SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse
ES2958720T3 (es) 2015-06-10 2024-02-13 Immunitybio Inc Células NK-92 modificadas para tratar el cáncer
JP6974311B2 (ja) 2015-06-23 2021-12-01 メモリアル スローン ケタリング キャンサー センター 新規ｐｄ−１免疫調節剤
AU2016285868B2 (en) 2015-06-30 2021-11-11 Nanotics, Llc Compositions and methods related to scavenger particles
CN108135850A (zh) 2015-07-29 2018-06-08 纳米提克斯有限责任公司 用于清除可溶性生物分子的模块化组合物及其相关方法
WO2017023780A1 (en) 2015-07-31 2017-02-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates for targeting cd56-positive tumors
TWI603980B (zh) * 2015-09-01 2017-11-01 免疫功坊股份有限公司 用以治療病理性血栓的聯合接合物構型藥物
JP7299021B2 (ja) 2015-09-11 2023-06-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 生体関連の直交性サイトカイン／受容体ペア
BR112018006237A2 (pt) 2015-09-29 2018-10-09 Celgene Corp proteínas de ligação a pd-1 e métodos de uso das mesmas
AU2016332900C1 (en) 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
KR102908806B1 (ko) 2015-10-22 2026-01-07 주노 테라퓨틱스 게엠베하 세포의 배양 방법 및 이를 위한 키트와 장치
ES2982752T3 (es) 2015-10-22 2024-10-17 Iltoo Pharma Composiciones farmacéuticas de il-2
EP3365369A1 (en) 2015-10-23 2018-08-29 Pfizer Inc Anti-il-2 antibodies and compositions and uses thereof
TW201726149A (zh) 2015-10-23 2017-08-01 理查 Ｐ 榮漢斯 用於免疫療法之組合方法
EP3371311B1 (en) 2015-11-06 2021-07-21 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
HUE054131T2 (hu) 2015-11-19 2021-08-30 Revitope Ltd Funkcionális ellenanyag-fragmens-komplementáció nemkívánatos sejtek elpusztítására szolgáló kétkomponensû rendszerben
US10597466B2 (en) 2015-12-02 2020-03-24 Fred Hutchinson Cancer Research Center Circular tandem repeat proteins
WO2017096262A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
IL313608A (en) 2015-12-09 2024-08-01 Hoffmann La Roche Antibody against CD20 type II to reduce the formation of antibodies against drugs
WO2017102010A1 (en) 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
WO2017107914A1 (zh) 2015-12-21 2017-06-29 合肥立方制药股份有限公司 一种药物设计方法和获得的药物及其应用
WO2017123675A1 (en) 2016-01-11 2017-07-20 Synlogic, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
EP3402818A1 (en) 2016-01-11 2018-11-21 Universität Zürich Combination therapy comprising a superagonistic antibody against interleukin-2 and a checkpoint blockade agent
JP6993699B2 (ja) 2016-01-11 2022-02-03 ウニヴェルズィテート・ツューリヒ ヒトインターロイキン－２に対する免疫刺激性ヒト化モノクローナル抗体及びその融合タンパク質
JP7292877B2 (ja) 2016-01-14 2023-06-19 イントレクソン・アクトバイオテイクス・エヌブイ １型糖尿病を処置するための組成物および方法
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
CN109071632B (zh) 2016-02-05 2022-12-30 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
US11053293B2 (en) 2016-02-05 2021-07-06 Washington University Compositions and methods for targeted cytokine delivery
WO2017139570A1 (en) 2016-02-12 2017-08-17 Massachusetts Intitute Of Technology Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccinne
EP3211000B1 (en) 2016-02-25 2019-01-30 Provecs Medical GmbH Novel immunostimulating vector system
US11248057B2 (en) 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies
MX2018010850A (es) 2016-03-10 2019-05-15 Univ Johns Hopkins Métodos para producir proteínas de fusión de toxina diftérica monoméricas y libres de agregados y usos terapéuticos.
US10898576B2 (en) 2016-03-16 2021-01-26 Yanhui Xie Glucocorticoid combined with polyethylene glycol-modified interleukin 2 for treating respiratory disease
WO2017158436A1 (en) 2016-03-17 2017-09-21 Oslo Universitetssykehus Hf Fusion proteins targeting tumour associated macrophages for treating cancer
WO2017178562A1 (en) 2016-04-12 2017-10-19 Philogen S.P.A. Combination therapy comprising an inflammatory immunocytokine and a chimeric antigen receptor (car)-t cell
EP3443003B1 (en) 2016-04-15 2020-12-30 Philogen S.p.A. Non-glycosylated anti-tenascin antibody
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US20190216898A1 (en) 2016-05-06 2019-07-18 Wang Mulin Interleukin Combination and Use Thereof
GB201608192D0 (en) 2016-05-10 2016-06-22 Immunovia Ab Method, array and use thereof
US12202856B2 (en) 2016-05-19 2025-01-21 The General Hospital Corporation Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity
MX2018014432A (es) 2016-05-25 2019-04-01 Hoffmann La Roche Materiales y metodos relacionados con el diseño del regimen de dosificacion.
EP3735984A1 (en) 2016-05-27 2020-11-11 Etubics Corporation Neoepitope vaccine compositions and methods of use thereof
JP2019517522A (ja) 2016-06-03 2019-06-24 エトゥビクス コーポレーション ヒトパピローマウイルス（ｈｐｖ）関連疾患の処置のための組成物及び方法
US20190125852A1 (en) 2016-06-03 2019-05-02 Etubics Corporation Compositions and methods for tumor vaccination using prostate cancer-associated antigens
CA3026345A1 (en) 2016-06-03 2017-12-07 Etubics Corporation Compositions and methods for tumor vaccination and immunotherapy involving her2/neu
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
IL263874B2 (en) 2016-06-22 2025-02-01 David Klatzmann Genetically modified T lymphocytes
CN109689086A (zh) 2016-07-11 2019-04-26 国家生物技术研究所公司 具有延长的血清半衰期的融合蛋白
EP3484509A4 (en) 2016-07-15 2020-03-25 Etubics Corporation COMPOSITIONS AND METHODS FOR VACCINATION AGAINST FLAVIVIRUS
CA3030451C (en) 2016-07-15 2023-09-05 Etubics Corporation Compositions and methods for alphavirus vaccination
IL264439B2 (en) 2016-08-17 2024-08-01 Factor Bioscience Inc non-viral, cell-free composition comprising a synthetic messenger RNA (MRNA) encoding a gene-editing protein for use in treating cancer, and a synthetic RNA encoding a gene-editing protein for use in treatment
GB201614093D0 (en) 2016-08-17 2016-09-28 Autolus Ltd Vector
CA3034266A1 (en) 2016-08-19 2018-02-22 Brooklyn Immunotherapeutics Llc Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancer
JP2020501508A (ja) 2016-09-15 2020-01-23 クアドルセプト バイオ リミテッド 多量体、四量体および八量体
EP3515944A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHOD FOR TREATING IMMUNE DISEASES USING PD-1 BINDING PROTEINS
EP3515943A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
CA3036564A1 (en) 2016-09-23 2018-03-29 Elstar Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
KR20190049887A (ko) 2016-09-29 2019-05-09 난트케이웨스트, 인크. 감소된 면역원성을 갖는 hla 클래스 i-결핍 nk-92 세포
EP3538548A4 (en) 2016-11-08 2020-08-19 Delinia, Inc. IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
CA3043597A1 (en) 2016-11-10 2018-05-17 Nektar Therapeutics Immunotherapeutic tumor treatment method
US10011269B2 (en) 2016-11-30 2018-07-03 Ford Global Technologies, Llc Identifying in-range fuel pressure sensor error
CN110177564A (zh) 2016-12-13 2019-08-27 德里尼亚公司 多价的调节t细胞调节剂
US20190352361A1 (en) 2016-12-15 2019-11-21 The Brigham And Women`S Hospital, Inc. Tissue-based biologics for the treatment of inflammatory and autoimmune disorders
CN110325205B (zh) 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
US10232053B2 (en) 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
US11065345B2 (en) 2017-01-04 2021-07-20 Nanotics, Llc Methods for assembling scavenging particles
WO2018129188A1 (en) 2017-01-04 2018-07-12 Nanotics, Llc Methods for assembling scavenging particles
CN110168078B (zh) 2017-01-06 2024-05-14 免疫生物公司 具有降低的cd96/tigit表达的遗传修饰的nk-92细胞
AU2018205234B2 (en) 2017-01-06 2024-09-19 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (TILs) with tumor necrosis factor receptor superfamily (TNFRSF) agonists and therapeutic combinations of TILs and TNFRSF agonists
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
EP3568150A4 (en) 2017-01-10 2020-12-02 Xcella Biosciences, Inc. POLYTHERAPY FOR TUMOR TREATMENT WITH INTEGRIN-BOUND FC FUSION PROTEIN AND IMMUNE MODULATOR
CA3052463A1 (en) 2017-02-03 2018-08-09 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Oncolytic virus therapy
PT3583125T (pt) 2017-02-16 2025-04-04 Sonnet Biotherapeutics Inc Proteínas de fusão ao domínio de ligação à albumina
US11318164B2 (en) 2017-03-01 2022-05-03 Nektar Therapeutics Immunotherapeutic treatment method using an interleukin-2 receptor beta-selective agonist in combination with adoptive cell transfer therapy
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
KR20240005989A (ko) 2017-03-15 2024-01-12 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
JP7148539B2 (ja) 2017-04-03 2022-10-05 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 免疫抱合体
KR102461885B1 (ko) 2017-04-03 2022-11-03 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
CN108686202A (zh) 2017-04-06 2018-10-23 张晋宇 肿瘤免疫疗法
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
KR20190136076A (ko) 2017-04-13 2019-12-09 에프. 호프만-라 로슈 아게 암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
CN121343934A (zh) 2017-05-10 2026-01-16 制药五有限责任公司 对补体灭活作用具有抗性的用于治疗癌症的包膜病毒
WO2018209115A1 (en) 2017-05-10 2018-11-15 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2018213192A1 (en) 2017-05-15 2018-11-22 University Of Miami Materials and methods for subjects at risk for viral reactivation
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US20210277085A1 (en) 2017-05-24 2021-09-09 Pandion Therapeutics, Inc. Targeted immunotolerance
KR102920712B1 (ko) 2017-05-24 2026-01-30 노파르티스 아게 항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
US20200362058A1 (en) 2017-05-24 2020-11-19 Novartis Ag Antibody-cytokine engrafted proteins and methods of use
TW201919662A (zh) 2017-06-05 2019-06-01 美商艾歐凡斯生物治療公司 對雙重難治性黑色素瘤使用腫瘤浸潤性淋巴細胞之方法
US20200199247A1 (en) 2017-06-07 2020-06-25 Silverback Therapeutics, Inc. Antibody conjugates of immune-modulatory compounds and uses thereof
US11241485B2 (en) 2017-06-12 2022-02-08 Obsidian Therapeutics, Inc. PDE5 compositions and methods for immunotherapy
WO2018228442A1 (en) 2017-06-14 2018-12-20 Dingfu Biotarget Co., Ltd. Proteinaceous heterodimer and use thereof
AU2018287317B2 (en) 2017-06-19 2024-06-20 Medicenna Therapeutics Inc. Uses and methods for IL-2 superagonists, agonists, and fusions thereof
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
US20200306301A1 (en) 2017-07-03 2020-10-01 Torque Therapeutics, Inc. Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof
AU2018301668A1 (en) 2017-07-12 2019-12-19 Synlogic Operating Company, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
US20190023760A1 (en) 2017-07-24 2019-01-24 Eth Zurich Method for preparing interleukin-2 or interleukin-2 analogues
IL321812A (en) 2017-08-03 2025-08-01 Synthorx Inc Cytokine complexes for the treatment of autoimmune diseases
KR20250020679A (ko) 2017-08-04 2025-02-11 젠맵 에이/에스 Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
CN117924493A (zh) 2017-08-09 2024-04-26 奥里尼斯生物科学有限公司 Clec9a结合剂及其用途
EP3664829A4 (en) 2017-08-09 2021-05-05 Orionis Biosciences, Inc. LIAISON OFFICERS AT PD-1 AND PD-L1
EP3665201A4 (en) 2017-08-09 2021-06-02 Orionis Biosciences, Inc. CD8 BINDERS
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
MX2020001879A (es) 2017-08-18 2020-07-29 Gritstone Oncology Inc Proteínas de fijación al antígeno que se dirigen a antígenos compartidos.
US20210115453A1 (en) 2017-08-31 2021-04-22 Poseida Therapeutics, Inc. Transposon system and methods of use
WO2019051127A1 (en) 2017-09-07 2019-03-14 Cue Biopharma, Inc. MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
MX2020002596A (es) 2017-09-07 2020-07-20 Cue Biopharma Inc Polipeptidos moduladores de linfocitos t multimericos y metodos de uso de estos.
WO2019051126A1 (en) 2017-09-07 2019-03-14 Cue Biopharma, Inc. ANTIGEN PRESENTING POLYPEPTIDES COMPRISING CHEMICAL CONJUGATION SITES AND METHODS OF USE THEREOF
EP3678677A4 (en) 2017-09-07 2021-06-16 Cue Biopharma, Inc. ANTIGEN-PRESENTING POLYPEPTIDES AND METHOD FOR THEIR USE
JP2020532987A (ja) 2017-09-08 2020-11-19 ポセイダ セラピューティクス，インコーポレイティド キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法
KR20200057051A (ko) 2017-09-27 2020-05-25 시질론 테라퓨틱스, 인크. 활성 세포를 포함하는 방법, 조성물 및 이식 가능한 요소
EP3689903A4 (en) 2017-09-30 2022-01-12 Hefei Lifeon Pharmaceutical Co. Ltd. BINDING OF PROTEIN TO FIBRONECTIN B DOMAIN
US11474271B2 (en) 2017-10-24 2022-10-18 Schlumberger Technology Corporation Methods and systems for automated sonic imaging
WO2019084284A1 (en) 2017-10-27 2019-05-02 Coneksis, Inc. NK CELLS FOR USE IN THE TREATMENT OF CANCER IN DOGS
US12564632B2 (en) 2017-11-08 2026-03-03 Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. Conjugates of biomolecule and use thereof
JP2021502422A (ja) 2017-11-13 2021-01-28 エクストレモチェム・エルディーエー．Ｅｘｔｒｅｍｏｃｈｅｍ，Ｌｄａ． 生体分子の安定剤としての中性のグリコシル化されたアミド及びジアニオン性のグルクロン酸化された酸
JP7557367B2 (ja) 2017-11-17 2024-09-27 アイオバンス バイオセラピューティクス，インコーポレイテッド 細針吸引及び小生検からのｔｉｌ拡大培養
KR102777151B1 (ko) 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
JP2021503885A (ja) 2017-11-22 2021-02-15 アイオバンス バイオセラピューティクス，インコーポレイテッド 末梢血からの末梢血リンパ球（ｐｂｌ）の拡大培養
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3720871A4 (en) 2017-12-06 2021-09-15 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
US11780899B2 (en) 2017-12-06 2023-10-10 The Board Of Trustees Of The Leland Stanford Junior University Engineered proteins to enhance sensitivity of a cell to IL-2
KR20240115352A (ko) 2017-12-06 2024-07-25 팬디온 오퍼레이션스, 인코포레이티드 Il-2 뮤테인 및 그 용도
CA3082204A1 (en) 2017-12-13 2019-06-20 Janssen Biotech, Inc. Immortalized car-t cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression
EP3724885A2 (en) 2017-12-15 2020-10-21 Iovance Biotherapeutics, Inc. Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
EP3502139A1 (en) 2017-12-19 2019-06-26 Philogen S.p.A. Antibodies to tumour antigens
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
JP7765181B2 (ja) 2017-12-19 2025-11-06 ゼンコア インコーポレイテッド 改変されたｉｌ－２ ｆｃ融合タンパク質
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
AU2018393110B2 (en) 2017-12-20 2023-04-27 Poseida Therapeutics, Inc. VCAR compositions and methods for use
US11970537B2 (en) 2017-12-26 2024-04-30 Nanjing GenScript Biotech Co., Ltd. Fusion protein dimer using antibody Fc region as backbone and use thereof
CN111868079B (zh) 2017-12-27 2025-06-17 协和麒麟株式会社 Il-2变体
JP2021508478A (ja) 2017-12-28 2021-03-11 ユリウス・マクシミリアンス−ウニヴェルジテート・ヴュルツブルクＪｕｌｉｕｓ Ｍａｘｉｍｉｌｉａｎｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｗｕｅｒｚｂｕｒｇ ＦｃγＲ非依存性アゴニスト活性がある腫瘍壊死因子（ＴＮＦ）受容体スーパーファミリー（ＴＮＦＲＳＦ）受容体活性化抗体融合タンパク質（ＦｃγＲ非依存性アゴニスト活性があるＴＮＦＲＳＦ受容体活性化抗体融合タンパク質；ＴＲＡＡＦＦＩＡＡ）
EP3737743A1 (en) 2018-01-08 2020-11-18 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2019144309A1 (en) 2018-01-24 2019-08-01 Beijing Percans Oncology Co. Ltd. Cytokine Fusion Proteins
JP7534215B2 (ja) 2018-01-24 2024-08-14 ベイジン パーカンズ オンコロジー カンパニー リミテッド サイトカイン融合タンパク質
TWI708787B (zh) 2018-03-02 2020-11-01 美商美國禮來大藥廠 Pd-1促效劑抗體及其用途
BR112020018049A2 (pt) 2018-03-07 2020-12-29 Poseida Therapeutics, Inc. Composições de cartirina e métodos para uso
CA3115461A1 (en) 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
JP2021530223A (ja) 2018-07-09 2021-11-11 スロゼン， インコーポレイテッド 組織特異性Ｗｎｔシグナル増強分子及びその使用
US12522640B2 (en) 2018-07-24 2026-01-13 BioNTech SE IL2 agonists
WO2020061142A1 (en) 2018-09-18 2020-03-26 Pandion Therapeutics, Inc. Targeted immunotolerance
MX2021006930A (es) 2018-12-11 2021-11-17 Q32 Bio Inc Construcciones de proteínas de fusión para enfermedades asociadas al complemento.
US20220106398A1 (en) 2019-02-08 2022-04-07 Igm Biosciences, Inc. Anti-gitr antigen-binding domains and uses thereof
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
US11095944B2 (en) 2019-08-19 2021-08-17 Roku, Inc. Content-modification system with broadcast schedule utilization feature
CN114728179A (zh) 2019-08-19 2022-07-08 潘迪恩运营公司 利用pd-1激动剂的靶向免疫耐受
WO2021168192A2 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with pd-1 agonists or il-2 muteins
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
JP2023538367A (ja) 2020-08-19 2023-09-07 パンディオン・オペレーションズ・インコーポレイテッド マルチパラトピック抗ｐｄ－１抗体およびその用途
EP4229078A4 (en) 2020-10-16 2025-03-19 Pandion Operations, Inc. Skin targeted immunotolerance
EP4229097A4 (en) 2020-10-16 2025-04-23 Pandion Operations, Inc. IMMUNOTOLERANCY TARGETING THE KIDNEY

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008505606A (ja) * 2004-01-09 2008-02-28 ファイザー インコーポレイティッド ＭＡｄＣＡＭに対する抗体
JP2012515778A (ja) * 2009-01-21 2012-07-12 アムジェン インコーポレイテッド 炎症性疾患および自己免疫疾患の処置の組成物および方法
JP2016514161A (ja) * 2013-03-14 2016-05-19 アムジエン・インコーポレーテツド アグリコシル化Ｆｃ含有ポリペプチド

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IMMUNOLOGY AND CELL BIOLOGY, vol. 93, JPN6022010836, 13 January 2015 (2015-01-13), pages 355 - 363, ISSN: 0004898106 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021507690A (ja) * 2017-12-06 2021-02-25 パンディオン・オペレーションズ・インコーポレイテッド Ｉｌ−２ムテインおよびその使用
JP7250790B2 (ja) 2017-12-06 2023-04-03 パンディオン・オペレーションズ・インコーポレイテッド Ｉｌ－２ムテインおよびその使用
JP2024524534A (ja) * 2021-07-09 2024-07-05 ブライト ピーク セラピューティクス エージー 炎症性疾患及び自己免疫疾患の治療のための修飾ｉｌ－２ポリペプチド

Also Published As

Publication number Publication date
US10676516B2 (en) 2020-06-09
US20210094996A1 (en) 2021-04-01
CN111010866A (zh) 2020-04-14
WO2018217989A1 (en) 2018-11-29
CA3064435A1 (en) 2018-11-29
IL270741A (en) 2020-01-30
US11466068B2 (en) 2022-10-11
AU2018273914A1 (en) 2019-11-14
KR20200010354A (ko) 2020-01-30
SG11201909949XA (en) 2019-11-28
EP3630163A4 (en) 2021-06-09
BR112019024127A2 (pt) 2020-06-23
MX2019013517A (es) 2020-08-17
EP3630163A1 (en) 2020-04-08
US20180340014A1 (en) 2018-11-29

Similar Documents

Publication Publication Date Title
US11466068B2 (en) Targeted immunotolerance
JP7165717B2 (ja) 標的免疫寛容
US11739146B2 (en) MAdCAM targeted immunotolerance
JP2022544990A (ja) Ｐｄ－１アゴニストによる標的化免疫容
US20220041713A1 (en) Targeted immunotolerance
US11981715B2 (en) Tissue targeted immunotolerance with a CD39 effector
JP2021505156A (ja) 標的化免疫寛容
EP4107189A2 (en) Tissue targeted immunotolerance with pd-1 agonists or il-2 muteins
US20210277085A1 (en) Targeted immunotolerance
HK40019692A (en) Targeted immunotolerance
HK40015990A (en) Targeted immunotolerance

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210511

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220322

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220622

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221018